Clinical Trials Insight: 700027165
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 15 Apr 2008
At a glance
- Drugs Sparsentan (Primary)
- Indications Diabetic nephropathies; Hypertension
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Pharmacopeia
- 15 Apr 2008 Interim results will be reported at ASH 2008 (abstract P-14).
- 04 Dec 2007 Additional positive safety results reported in a Pharmacopeia media release.
- 29 Sep 2007 Early results have indicated no safety or tolerability issues. As a result, the study will be expanded to include a 1000mg dose. The Company expects to report findings from this dose later in 2007.